There’s a new drug to treat Alzheimer’s disease, but those who might benefit from it know almost nothing about it, a new study shows.
In spring 2021, for the first time in decades, the U.S. Food and Drug Administration approved a drug to treat Alzheimer’s disease. Enthusiasm for the drug, aducanumab, was swiftly eclipsed by concerns about efficacy, prohibitive cost and serious side effects.
Now, USC researchers have found older Americans most at risk for Alzheimer’s know little about aducanumab (brand name Aduhelm™), despite the fact that an overwhelming majority of survey respondents said they were worried about Alzheimer’s disease. The study appears this week in JAMA Network Open.
“The contrast between older Americans who were very concerned about developing Alzheimer’s disease and those that actually knew anything about the drug was surprising,” said Julie Zissimopoulos, the lead study author, associate professor at the USC Price School of Public Policy and a senior fellow at the USC Schaeffer Center for Health Policy & Economics.
Study looks at older Americans’ knowledge about new Alzheimer’s drug
Shortly after the FDA’s decision, the study authors sought to understand older Americans’ knowledge of and opinions about aducanumab and its potential outcomes.
The researchers analyzed more than 1,000 responses to an online survey of people 55 and older who are part of the USC Center for Economic and Social Research large online survey panel, Understanding America Study. The responses, collected just a few weeks after the June 2021 approval, revealed that although more than 8 in 10 respondents were concerned about Alzheimer’s disease, only about 1 in 4 had some knowledge of the drug.